Literature DB >> 10709745

Treatment-resistant expansion of CD8+CD28-cells in pediatric HIV infection.

T Niehues1, G Horneff, S Knipp, O Adams, V Wahn.   

Abstract

There is a disease stage-dependent loss of CD28 expression on T cells in HIV-infected children. In this study, T cell recovery, in particular CD28 expression on T cells, was analyzed after initiation of highly active antiretroviral therapy in a group of eight mostly treatment-naive HIV-infected children. Plasma HIV-RNA levels were recorded, and numbers of CD4, CD8, CD4+CD28+, and CD8+CD28+ cells were determined by two-color flow cytometry. Values after 12 mo of therapy were compared with age-matched, seronegative control subjects. CD4 recovery to subnormal values was observed in all children. CD8+CD28+ cells recovered and were within the normal range after 12 mo of therapy (patients, 703 +/- 250 cells/microL; controls, 789 +/- 269 cells/microL), whereas CD8+CD28- cells (546 +/- 269 cells/microL) remained significantly expanded compared with age-matched controls (140 +/- 35 cells/microL). Expansions of CD8+CD28- cells persisted even in cases with long-term suppression of viral replication. Highly active antiretroviral therapy in HIV-infected children induces substantial but incomplete T cell recovery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709745     DOI: 10.1203/00006450-200003000-00022

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

1.  The developing human immune system: T-cell receptor repertoire of children and young adults shows a wide discrepancy in the frequency of persistent oligoclonal T-cell expansions.

Authors:  L R Wedderburn; A Patel; H Varsani; P Woo
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART).

Authors:  D J King; F M Gotch; E L Larsson-Sciard
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

3.  Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.

Authors:  Christos Tsoukas; Louise Gilbert; Trevor Lewis; George Hatzakis; Ron Falcon; Joseph Mrus
Journal:  ISRN AIDS       Date:  2013-12-12

4.  Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial.

Authors:  Talía Sainz; Laura Diaz; David Rojo; María Isabel Clemente; Coral Barbas; María José Gosalbes; Nuria Jimenez-Hernandez; Luis Escosa; Sara Guillen; José Tomás Ramos; María Ángeles Muñoz-Fernández; María Luisa Navarro; María José Mellado; Sergio Serrano-Villar
Journal:  Nutrients       Date:  2022-02-26       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.